Because some first generation artificial pancreases only dispense insulin, researchers are looking to ensure that people can prevent very low sugar levels, or hypoglycemia. In people that don’t have diabetes, insulin works in concert with glucagon, which is usually produced by the alpha cells in the pancreas. The delicate balance of both hormones hasn’t been replicated in humans by a mechanical gadget – as yet. W. Kenneth Ward, M.D., a senior scientist at Legacy Health, led a mixed group that investigated the mixture glucagon and insulin therapy in an artificial pancreas. There were 21 experiments where the gadget was tested for about 24 hours, and the incidence of hypoglycemia was markedly reduced.This is a 2-cent, or 14.3 percent, increase over the 14-cent dividend paid in the second quarter of 2011. In August 2010 The previous dividend increase was, when the Board elevated the dividend from 12-cents to 14-cents per share. This represents the 161st consecutive quarterly dividend paid by Chemed in its 40 years as a public firm. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation misalign or become trapped and interfere with the function of the central nervous system .